Expert Details

Expert in Pharmaceutical Licensing Partnerships and Intellectual Property Disputes

Expert ID: 731634 New Jersey, USA

Request Expert

Consultant (2012- present) Clients include Merck Research Laboratories, Drais Pharmaceuticals and Unigene, a small biotechnology company.For Merck, part of project team overseeing various research projects within the respiratory and cardiovascular therapies. Responsibilities include review of protocol, interfacing with CROs, medical team and legal. At Unigene, (a peptide drug delivery company), identified corporate partners for their nascent technology.

Education

Year Degree Subject Institution
Year: 1972 Degree: MBA Subject: Finance Institution: New York University

Work History

Years Employer Title Department Responsibilities
Years: 2006 to 2012 Employer: MicroDose Therapeutx Title: VP Department: Business Development Responsibilities: MicroDose Therapeutx (venture backed drug Delivery Company merged with Teva). He completed the largest partnerships in the Company’s history by licensing basic technology to Merck and Novartis and Gilead Sciences. These partnerships required joint product development and sharing intellectual property. Out-licensed a viral therapy to Gilead Sciences, the leading global virology company. In licensed, nascent technology to telephonically relay data from the patient to physician and a preclinical therapy for a gastrointestinal disease.
Years: 2002 to 2005 Employer: Odyssy Pharmaceticals Title: Sr Director Department: Business Development Responsibilities: Odyssey Pharmaceuticals (a $100 mm subsidiary of foreign generic company which merged with Teva) He completed a partnership and a joint product development program for a urology product which established this small company as a major specialty pharmaceutical company.
Years: 1999 to 2002 Employer: Hoffmann La Roche Title: Director Department: Business development Responsibilities: Director of Global Business Development: He identified, analyzed and negotiated pharmaceutical licensing, copromotion and acquisition opportunities. Assessed technology in several therapeutic areas. Instrumental in building the Oncology business through the acquisition of Kytril ($350mm in sales) and identifying and evaluating the license of Tarceva, a novel oncology compound with sales over $2 billion Out licensing and planning responsibilities. Generic partnering strategies.
Years: 1994 to 1999 Employer: Sanofi-Aventis Title: Assosiate Director Department: Licensing-Business Development Responsibilities: for this US subsidiary of a $20 billion French pharmaceutical company,He identified, analyzed and negotiated pharmaceutical licensing and acquisition opportunities. Assessed technology in several therapeutic areas: cardiovascular, oncology, CNS and anti-inflammatory. Interfaced with market research, research and development and foreign parent to forecast and value transactions. Provided analysis of deal structure and conducted negotiations. Concluded a co-promotion agreement for a cardiovascular drug which was the first such agreement for the US operation and contributed $5mm in profits. Proposed and negotiated the license an ant-inflammatory drug which contributed $70mm in sales. Completed the acquisition of Bock Pharmacal, which provided a US infrastructure and US sales force.

Government Experience

Years Agency Role Description
Years: 2011 to 2011 Agency: Department of Defense Role: Secured $1mm grant Description: Licensed drug delivery technology to the DOD and resolved joint intellectual ownership issues.

International Experience

Years Country / Region Summary
Years: 1999 to 2003 Country / Region: Switzerland Summary: Worked for Swiss based pharmaceutical company.
Years: 1994 to 1999 Country / Region: France Summary: Worked for Paris based pharmaceutical company

Career Accomplishments

Associations / Societies
Licensing Executive Society
Awards / Recognition
Received award for one of the best Journal articles:
Negotiating Pharmaceutical Licenses” Les Nouvelles 9/09
Publications and Patents Summary
“Valuing Products in New Market Areas: A Business Development Perspective”
“Successful Pharmaceutical Acquisitions of Biotechnology Companies”
“Off Loading Risk-Out-licensing as a Business Development Function”
Articles: “In-Licensing Discontinued Pharmaceutical Products: finding the Rembrandt in the Attic.” and “Negotiating Pharmaceutical Licenses” Les Nouvelles 1/06; 9/09.
Patent Application (sole inventor) for a novel drug to treat Chronic Obstructive Pulmonary Disease.

Additional Experience

Expert Witness Experience
None
Training / Seminars
Speeches at international health care conferences:
“Valuing Products in New Market Areas: A Business Development Perspective”
“Successful Pharmaceutical Acquisitions of Biotechnology Companies”
“Off Loading Risk-Out-licensing as a Business Development Function”
Vendor Selection
He has great experience with contacting patent law firms, multiple pharmaceutical and medical device companies.
Marketing Experience
Published various article in industry journals:
“In-Licensing Discontinued Pharmaceutical Products: finding the Rembrandt in the Attic.” and “Negotiating Pharmaceutical Licenses” Les Nouvelles 1/06; 9/09.

Other Relevant Experience
Patent Application (sole inventor) for a novel drug to treat Chronic Obstructive Pulmonary Disease. Now being developed by a multi-national pharmaceutical company.

Fields of Expertise

Request Expert

Dev Tool:

Request: expert/pharmaceutical-licensing-partnerships-and-intellectual-property-disputes
Matched Rewrite Rule: expert/([^/]+)(?:/([0-9]+))?/?$
Matched Rewrite Query: experts=pharmaceutical-licensing-partnerships-and-intellectual-property-disputes&page=
Loaded Template: single-experts.php